课题基金 / 基金详情

PHASE 1B STUDY OF REPETITIVE DAILY IV DOSES OF RSR13 FOR GLIOBLASTOMA

PHASE 1B STUDY OF REPETITIVE DAILY IV DOSES OF RSR13 FOR GLIOBLASTOMA
每日重复 IV 剂量 RSR13 治疗胶质母细胞瘤的 1B 期研究
批准号：
6122758
负责人：
GLENN J LESSER
金额：
$3.88万
依托单位：
WAKE FOREST UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6122758
关键词：
clinical research clinical trial phase I drug screening /evaluation glioblastoma multiforme human subject intravenous administration neoplasm /cancer radiation therapy radiopharmacology radiosensitizer

项目摘要

项目成果

GLENN J LESSER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
RSR 13 is a synthetic allosteric modifer of hemoglobin. It decreases the oxygen affinity of hemoglobin and augments oxygen unloading in the microvasculature which increases the oxygen diffusion gradient to the tissues. By increasing tissue oxygenation, RSR 13 may reduce tumor hypoxia and enhance the cytotoxic effects of radiation therapy used to treat cancer patients with solid tumors. This study will therefore evaluate the safety and toxicity of this new agent and its efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
海外基金